Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib in Adenoid Cystic Carcinoma
NCT02098538Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2014
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of regorafenib in adenoid cystic carcinoma (ACC), sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT02098538.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02098538.